Status: Recruiting
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (HSCT) with treatment refractory post-transplant viral infections. The CCS has already been successfully used in clinical studies in Germany and United Kingdom (UK).
Participants needed: 30
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: University Hospital, Basel, SwitzerlandUpdated: Mar 20, 2025Locations: 1
Eligibility criteria
Adults > 18 years of age [+12]
graft-versus-host disease (GVHD) > grade 2 at the time point of planned infusion [+1]